Scholarlink

Purpose <p>Calcified chondroid mesenchymal neoplasm (CCMN) is a recently described and evolving entity that predominantly arises in the distal extremities andtemporomandibular joint (TMJ) region. CCMN is characterized by <i>FN1</i> and <i>PDGFRA</i> gene fusions. In the TMJ region, most cases previously described as tophaceous pseudogout (i.e., mass-forming calcium pyrophosphate deposition disease) are now being increasingly recognized as CCMN. There is considerable morphologic overlap between CCMN and tophaceous pseudogout (TPG), and the detection of <i>FN1</i> and <i>PDGFRA</i> gene rearrangements is critical in distinguishing CCMN from TPG. We aim to identify, from our archival records, cases of CCMN that were previously diagnosed as TPG.</p> Methods <p>We retrospectively reviewed clinical history and histopathology slides of three cases of TMJ region masses initially diagnosed as TPG, and submitted all three cases for targeted RNA sequencing. Results: Case 1 harbored a canonical <i>FN1::FGFR2</i> fusion. Case 2 failed targeted RNA sequencing. Case 3 harbored a canonical <i>PDGFRA::USP8</i> fusion. None of the three cases had clinical history of pseudogout. All three cases were subsequently reclassified as CCMN on review.</p> Conclusion <p>CCMN should be considered as a differential diagnosis in first presentations of ‘tophaceous pseudogout’ associated with chondroid metaplasia, with targeted molecular testing done as part of the diagnostic process.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Calcified Chondroid Mesenchymal Neoplasm of the Temporomandibular Joint Region: Three Cases Illustrating Recent Developments and Diagnostic Pitfalls

  • 期刊论文

  • 发表日期：

    2026年7月21日

查看全文
  • Darren Yee Shuen Chua,
  • Xinyi Qu,
  • Bengt Fredrik Petersson,
  • Jaslyn Jie Lin Lee,
  • Ming Liang Oon,
  • Nicholas Jin Hong Tan,
  • Abbas Agaimy,
  • Bingcheng Wu

摘要

Purpose

Calcified chondroid mesenchymal neoplasm (CCMN) is a recently described and evolving entity that predominantly arises in the distal extremities andtemporomandibular joint (TMJ) region. CCMN is characterized by FN1 and PDGFRA gene fusions. In the TMJ region, most cases previously described as tophaceous pseudogout (i.e., mass-forming calcium pyrophosphate deposition disease) are now being increasingly recognized as CCMN. There is considerable morphologic overlap between CCMN and tophaceous pseudogout (TPG), and the detection of FN1 and PDGFRA gene rearrangements is critical in distinguishing CCMN from TPG. We aim to identify, from our archival records, cases of CCMN that were previously diagnosed as TPG.

Methods

We retrospectively reviewed clinical history and histopathology slides of three cases of TMJ region masses initially diagnosed as TPG, and submitted all three cases for targeted RNA sequencing. Results: Case 1 harbored a canonical FN1::FGFR2 fusion. Case 2 failed targeted RNA sequencing. Case 3 harbored a canonical PDGFRA::USP8 fusion. None of the three cases had clinical history of pseudogout. All three cases were subsequently reclassified as CCMN on review.

Conclusion

CCMN should be considered as a differential diagnosis in first presentations of ‘tophaceous pseudogout’ associated with chondroid metaplasia, with targeted molecular testing done as part of the diagnostic process.